Versant Ventures related stories
All articles and analysis
Alcon Buying LensX Lasers for $744 MillionAlcon Inc. (NYSE: ACL) has agreed to acquire LensX Lasers Inc., an Aliso Viejo, Calif.-based maker of cataract surgery lasers. The deal includes a $361.5 million up-front cash payment, plus up to $382.5 million in milestone payments. LensX has raised nearly $32 million in VC funding from Versant Ventures, InterWest Partners and SV Life Sciences. The LenxX founding team is the same group that founded IntraLase, a VC-backed company acquired by AMO in 2007 for $808 million.
- peHUB Wire: Wednesday, July 7, 2010
Random Ramblings
- peHUB Wire: Wednesday, July 7, 2010
Random Ramblings
- Veracyte Raises $28 Million
Veracyte Inc., a South San Francisco-based developer of molecular cytology diagnostics, has raised $28 million in Series B funding. Domain Associates led the round, and was joined by return backers Kleiner Perkins Caufield & Byers, TPG Biotech and Versant Ventures. Veracyte previously raised around $22 million.
- peHUB Wire: Thursday, June 10, 2010
Random Ramblings
- peHUB Wire: Thursday, June 10, 2010
Random Ramblings
- VC-Backed IPO Pipeline Remains Clogged
It's been a slow month for VC-backed IPOs, with just three new companies filing and three going public. In fact, only two even bothered to ammend their proposed pricing terms. The newbies were ZipCar, TripeWire and NuPathe, while the recently-listed were Accretive Health, JinkoSolar and TeleNav. That means the VC-backed IPO pipeline remains static with 43 total registrants, but also a bit lighter since the filers are seeking less money than were those that priced. Overall, VC-backed companies in registration to go public are aiming to raise nearly $4.5 billion. The full pipeline is after the jump...
Women in VCThink your venture job is tough? Try being a VC and a woman.
- Clovis Oncology Signs $209 Million R&D Deal with Avila Therapeutics
Clovis Oncology has signed a development and commercialization agreement for Avila Therapeutics' epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, which is in pre-clinical development for the treatment of non-small cell lung cancer. Avila will receive up to $209 million in up-front and clinical milestone payments, plus possible royalty and sub-licensing fees. Clovis Oncology last year raised $146 million in Series A funding from Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures and ProQuest Investments. Avila Therapeutics has raised over $51 million from The Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.
- Clovis Oncology Signs $209 Million R&D Deal with Avila Therapeutics
Clovis Oncology has signed a development and commercialization agreement for Avila Therapeutics' epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, which is in pre-clinical development for the treatment of non-small cell lung cancer. Avila will receive up to $209 million in up-front and clinical milestone payments, plus possible royalty and sub-licensing fees. Clovis Oncology last year raised $146 million in Series A funding from Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures and ProQuest Investments. Avila Therapeutics has raised over $51 million from The Novartis Option Fund, Abingworth Management, Advent Venture Partners, Atlas Venture and Polaris Venture Partners.